iLife Technologies Inc. v. Body Media, Inc.

90 F. Supp. 3d 415, 2015 U.S. Dist. LEXIS 24039, 2015 WL 868103
CourtDistrict Court, W.D. Pennsylvania
DecidedFebruary 27, 2015
DocketCivil Action No. 14-990
StatusPublished
Cited by1 cases

This text of 90 F. Supp. 3d 415 (iLife Technologies Inc. v. Body Media, Inc.) is published on Counsel Stack Legal Research, covering District Court, W.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
iLife Technologies Inc. v. Body Media, Inc., 90 F. Supp. 3d 415, 2015 U.S. Dist. LEXIS 24039, 2015 WL 868103 (W.D. Pa. 2015).

Opinion

MEMORANDUM OPINION

JOY FLOWERS CONTI, Chief Judge.

This patent infringement case involves five asserted patents, United States Patent Numbers 6,307,481 (the “'481 Patent”), 6,703,939 (the “'939 Patent”), 7,095,331 (the “'331 Patent”), 7,145,461 (the “'461 Patent”), and 7,479,890 (the “'890 Patent”), and twenty-seven asserted claims. (ECF No. 66-1 at 4.) iLife Technologies Inc.’s (“iLife”) complaint references a sixth patent, United States Patent Number 6,864,-796, but iLife confirmed at the technology tutorial that it no longer asserts any claims based upon that patent, and all such claims should be dismissed, with prejudice. (ECF No. 96 at 2) The patents, generally, disclose systems and methods for evaluating movement or activity of a body in relationship to an environment. (ECF No. 66 at 6.) The patents are all related, as is reflected in the below flow chart:

[419]*419[[Image here]]

(ECF No. 76 at 7.) This chart reflects that the first patent was applied for in 1999 and issued in 2001, and the most recent patent was applied for in 2006 and issued in 2009. The chart also reflects that although the patents are related, they fall into three distinct categories: (1) those that evaluate body movement (the '481 Patent, which is the parent patent); (2) those that detect body motion (the '939 and '331 Patents); and (3) those that analyze body activity (the '461 and '890 Patents). iLife is the owner by assignment of all the asserted patents.

The parties’ joint disputed claim terms chart asks this court to construe nine claim terms or phrases, and Body Media Inc. (“Body Media”) contends that nine other claim terms or phrases are indefinite, rendering the pertinent patent claims invalid. (ECF No. 64-1 at 3-11.)1 The parties agreed upon the construction of several claim terms that were originally disputed, and set forth the stipulated constructions at the beginning of the amended joint disputed claim terms chart. (Id. at 1-2.) Although the court is not bound by those proposals, as they ultimately concern a question of law, the court finds adequate [420]*420support for each agreed upon construction in the intrinsic record, and, therefore, adopts the parties’ stipulated constructions as set forth in the accompanying order. Labyrinth Optical Technologies, LLC v. Ciena Communications, Inc., No. 12-2217, 2013 WL 9602736, at *7 (C.D.Cal. Dec. 18, 2013) (citing Exxon Chemical Patents, Inc. v. Lubrizol Corp., 64 F.3d 1553, 1555 (Fed.Cir.1995); MyMail, Ltd. v. Am. Online, Inc., 476 F.3d 1372, 1377-78 (Fed.Cir.2007).) In addition, Body Media withdrew its proposed construction of two claim phrases, effectively agreeing with iLife’s position that the plain and ordinary meaning should apply for purposes of this case. (ECF No. 76 at 27 (indicating that the court need no longer construe “relative to a three dimensional frame of reference in said environment”/“with respect to sáid three dimensional frame of reference” and “no movement for a predetermined period of time”).) This court must, therefore, construe seven claim terms and decide whether nine claim terms are indefinite.

iLife filed an opening claim construction brief, to which Body Media responded. (ECF Nos. 66 and 76.) Both parties filed identifications of extrinsic evidence with their initial briefs. (ECF Nos. 67 and 77.) iLife filed a claim construction reply brief. (ECF No. 78.) On January 15, 2015, a technology tutorial was held. (ECF No. 96.) The next day, the court ordered the parties to make additional submissions directed specifically to the effect that disclosure of new matter in the continuation-in-part patents (i.e., the '939 and '461 Patents) might have on claim construction in this case. (1/16/2015 Text Order; ECF Nos. 98 and 99.) Following the Markman hearing, which was held on February 3, 2015, and as requested by the court, the parties filed a joint submission regarding the person of ordinary skill in the art. (ECF No. 101.)

The matter of claim construction is fully briefed. The primary claim construction disputes focus on whether the iLife patents disclose inventions that monitor any and all body2 movement, or only those movements (or lack of movements) that signify an abnormal or harmful event, such as a fall or a baby’s suffocation.

I. LEGAL STANDARDS

A. Generally Applicable Principles of Claim Construction

The general principles of claim construction are without dispute., The proper construction of a patent’s claims is a question of law. Teva Pharm. USA Inc. v. Sandoz, Inc., — U.S. -, 135 S.Ct. 831, 837, — L.Ed.2d- (2015) (citing Markman v. Westview Instruments, Inc., 517 U.S. 370, 388-91, 116 S.Ct. 1384, 134 L.Ed.2d 577 (1996)). The Supreme Court recently held that where a court must consider extrinsic evidence to arrive at the proper claim construction, the clearly erroneous standard of review applies to any subsidiary factual findings. Id. at 837-38, 841-42. “It is a ‘bedrock principle’ of patent law that ‘the claims of a patent define the invention to which the patentee is entitled the right to exclude.’ ” Phillips v. AWH Corp., 415 F.3d 1303, 1312 (Fed.Cir.2005) (en banc) (quoting Innova/Pure Water, Inc. v. Safari Water Filtration Sys., Inc., 381 F.3d 1111, 1115 (Fed.Cir.2004)). The words of a claim “are generally given their ordinary and customary meaning,” which “is the meaning that the term would have to a person of ordinary skill in the art in question at the time of the invention, i.e., as of the effective filing date of the patent application.” Id. at 1312-13 (citing Vitronics Corp. v. Conceptronic, Inc., 90 [421]*421F.3d 1576, 1582 (Fed.Cir.1996); Inno-va/Pure Water, 381 F.3d at 1116). In arriving at this meaning, a court is to look first and foremost- to the “intrinsic evidence,” which consists of the patent’s claim language, the specification and written description, and the prosecution history, to determine the meaning of disputed claim terms. Phillips, 415 F.3d at 1311-17; Medrad, Inc. v. MRI Devices Corp., 401 F.3d 1313, 1319 (Fed.Cir.2005). The specification is the single best guide to the meaning of a disputed term, and is “usually ... dispositive.” Phillips, 415 F.3d at 1315 (citing Vitronics, 90 F.3d at 1582).

Claim language guides the court’s construction of claim terms. Phillips, 415 F.3d at 1314. Yet, the “claims cannot enlarge what is patented beyond what the inventor has described as the invention.” Abbott Laboratories v. San-doz, Inc., 566 F.3d 1282, 1288 (Fed.Cir.2009) (citing Biogen, Inc. v. Berlex Labs., Inc., 318 F.3d 1132, 1140 (Fed.Cir.2003)). The context in which a term is used not only in the asserted claims, but also in any claims that are not being asserted in a particular lawsuit, can be highly instructive because “terms are normally used consistently throughout the patent.” Phillips, 415 F.3d at 1314.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Kane v. City of Ithaca
N.D. New York, 2019

Cite This Page — Counsel Stack

Bluebook (online)
90 F. Supp. 3d 415, 2015 U.S. Dist. LEXIS 24039, 2015 WL 868103, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ilife-technologies-inc-v-body-media-inc-pawd-2015.